Ajanta Pharma Ltd., the leading Mumbai-based pharmaceutical formulation company, continued its growth for the fourth consecutive year with an excellent performance. It posted a healthy growth of 39 per cent in net profit and 19 per cent in sales for the financial year ended March 31, 2006. The Profit After Tax (PAT) for the financial year 2005-'06 has grown to Rs 10.35 crore against Rs 7.44crore for the previous year with sales of Rs 212.37crore against Rs178.80 crore for the previous year. The Board has recommended a dividend of 15% on equity shares.
The consolidated sales for the year ended March 31, 2006 stood at Rs 236.07crore against Rs 202.03crore in the previous year, indicating a growth of 17 per cent. Consolidated profit after tax for the year was Rs12.35 crore against Rs 9.85 crore for the previous year.
After successfully establishing its marketing presence in more than 50 countries, the company is now exploring USA, the largest pharmaceutical market of the world. It is looking for tie-ups for contract research and manufacturing, acquisitions and in-licensing opportunities from the US market.